Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001851744 | SCV002241323 | pathogenic | Epidermolysis bullosa simplex 5B, with muscular dystrophy; Epidermolysis bullosa simplex, Ogna type; Epidermolysis bullosa simplex 5C, with pyloric atresia; Autosomal recessive limb-girdle muscular dystrophy type 2Q; Epidermolysis bullosa simplex with nail dystrophy | 2020-11-03 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the PLEC protein. Other variant(s) that disrupt this region (p.Ser4396*) have been determined to be pathogenic (Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with autosomal recessive epidermolysis bullosa (PMID: 15654962). ClinVar contains an entry for this variant (Variation ID: 8266). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Arg3029*) in the PLEC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 1546 amino acid(s) of the PLEC protein. |
OMIM | RCV000008755 | SCV000028964 | pathogenic | Epidermolysis bullosa simplex 5C, with pyloric atresia | 2005-01-01 | no assertion criteria provided | literature only |